Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY ...
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln
Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...
Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
The deal includes additional commercial milestone payments of up to $250 million and will be completed by year-end, subject ...
FiercePharma3d
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...
BioSpace3d
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...
MedCity News3d
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in a deal that helps the Italian company build its rare disease ...
BioPharma Dive3d
Sanofi’s rare disease drug finds yet another home
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
Recordati shares jump on deal with Sanofi for Enjaymo rights
Recordati 's (BIT: RECI) shares jumped on Friday following its deal with Sanofi (NASDAQ: SNY) to buy the global rights to ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million. The Italian pharmaceutical company said ...